Osaka, Japan – September 3, 2024 – Atransen Pharma is proud to announce that it has been selected for the Batch-19 Innovation Partner Program (IPP) of the prestigious “Berkeley SkyDeck Program” at the University of California, Berkeley.
Berkeley SkyDeck is one of the world’s leading startup acceleration programs offered by UC Berkeley. Located in the heart of Berkeley, the program provides selected startups with unparalleled mentorship, funding opportunities, and access to a vast global network, accelerating their path to global market entry. The IPP (Innovation Partner Program) is specifically designed to support cutting-edge deep-tech startups, fostering their growth through targeted incubation and acceleration initiatives.
“We are honored to be selected for Berkeley SkyDeck’s Batch-19 IPP. This program will be instrumental in advancing our next-generation drug discovery initiatives and expanding our presence in the global market,” said Tomoyuki Asano, CEO of Atransen Pharma.
Atransen Pharma is committed to pioneering innovative drug discovery targeting LAT1, aiming to develop novel therapies for diseases with significant unmet medical needs. Leveraging the support of Berkeley SkyDeck, the company will accelerate its research and development efforts, driving innovation and making a lasting impact in the pharmaceutical industry.
